Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Operating Leases (2022 - 2025)

Rani Therapeutics Holdings has reported Operating Leases over the past 4 years, most recently at $2.7 million for Q4 2025.

  • Quarterly results put Operating Leases at $2.7 million for Q4 2025, down 24.88% from a year ago — trailing twelve months through Dec 2025 was $2.7 million (down 24.88% YoY), and the annual figure for FY2025 was $2.7 million, down 24.88%.
  • Operating Leases for Q4 2025 was $2.7 million at Rani Therapeutics Holdings, down from $3.0 million in the prior quarter.
  • Over the last five years, Operating Leases for RANI hit a ceiling of $4.7 million in Q1 2024 and a floor of $59000.0 in Q4 2022.
  • Median Operating Leases over the past 4 years was $2.7 million (2025), compared with a mean of $2.1 million.
  • Biggest five-year swings in Operating Leases: plummeted 46.23% in 2023 and later surged 2249.12% in 2024.
  • Rani Therapeutics Holdings' Operating Leases stood at $59000.0 in 2022, then skyrocketed by 189.83% to $171000.0 in 2023, then surged by 2026.9% to $3.6 million in 2024, then dropped by 24.88% to $2.7 million in 2025.
  • The last three reported values for Operating Leases were $2.7 million (Q4 2025), $3.0 million (Q3 2025), and $3.2 million (Q2 2025) per Business Quant data.